Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

NCT01000740 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01000740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01000740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2009
Completion date
April 30, 2010
Enrollment
59 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer